Similar articles for PMID: 31941722

Year	Number of Results
1994	1
1996	1
1997	1
1998	1
2000	1
2001	4
2002	4
2003	2
2004	2
2005	3
2006	3
2007	1
2008	3
2009	5
2010	5
2011	4
2012	10
2013	7
2014	4
2015	7
2016	11
2017	3
2018	11
2019	9
2020	9
2021	8
2022	3
2024	0

1

Extracellular Vesicle-Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2⁺ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity.

Forterre AV, Wang JH, Delcayre A, Kim K, Green C, Pegram MD, Jeffrey SS, Matin AC. Forterre AV, et al. Mol Cancer Ther. 2020 Mar;19(3):858-867. doi: 10.1158/1535-7163.MCT-19-0928. Epub 2020 Jan 15. Mol Cancer Ther. 2020. PMID: 31941722 Free PMC article.

2

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.

Wang JH, Forterre AV, Zhao J, Frimannsson DO, Delcayre A, Antes TJ, Efron B, Jeffrey SS, Pegram MD, Matin AC. Wang JH, et al. Mol Cancer Ther. 2018 May;17(5):1133-1142. doi: 10.1158/1535-7163.MCT-17-0827. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483213 Free PMC article.

3

Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug.

Wang JH, Endsley AN, Green CE, Matin AC. Wang JH, et al. BMC Cancer. 2016 Jul 25;16:524. doi: 10.1186/s12885-016-2508-6. BMC Cancer. 2016. PMID: 27457630 Free PMC article.

4

mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo.

Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, Delcassian D, Anderson DG. Rybakova Y, et al. Mol Ther. 2019 Aug 7;27(8):1415-1423. doi: 10.1016/j.ymthe.2019.05.012. Epub 2019 May 18. Mol Ther. 2019. PMID: 31160223 Free PMC article.

5

Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.

O'Brien KP, Khan S, Gilligan KE, Zafar H, Lalor P, Glynn C, O'Flatharta C, Ingoldsby H, Dockery P, De Bhulbh A, Schweber JR, St John K, Leahy M, Murphy JM, Gallagher WM, O'Brien T, Kerin MJ, Dwyer RM. O'Brien KP, et al. Oncogene. 2018 Apr;37(16):2137-2149. doi: 10.1038/s41388-017-0116-9. Epub 2018 Jan 25. Oncogene. 2018. PMID: 29367765

6

Extracellular vesicle-mediated suicide mRNA/protein delivery inhibits glioblastoma tumor growth in vivo.

Erkan EP, Senfter D, Madlener S, Jungwirth G, Ströbel T, Saydam N, Saydam O. Erkan EP, et al. Cancer Gene Ther. 2017 Jan;24(1):38-44. doi: 10.1038/cgt.2016.78. Epub 2016 Dec 16. Cancer Gene Ther. 2017. PMID: 27982017

7

Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.

Sun J, Xu Y, Song S, Wu Z, Duan H. Sun J, et al. Pharm Biol. 2011 Nov;49(11):1167-72. doi: 10.3109/13880209.2011.575792. Pharm Biol. 2011. PMID: 22014264

8

Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.

Chen L, Waxman DJ. Chen L, et al. Curr Pharm Des. 2002;8(15):1405-16. doi: 10.2174/1381612023394566. Curr Pharm Des. 2002. PMID: 12052216 Review.

9

Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.

Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ, Harris PA, Mountain A, Wrighton CJ. Djeha AH, et al. Mol Ther. 2001 Feb;3(2):233-40. doi: 10.1006/mthe.2000.0250. Mol Ther. 2001. PMID: 11237680 Free article.

10

CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy.

Thorne SH, Barak Y, Liang W, Bachmann MH, Rao J, Contag CH, Matin A. Thorne SH, et al. Mol Cancer Ther. 2009 Feb;8(2):333-41. doi: 10.1158/1535-7163.MCT-08-0707. Epub 2009 Feb 3. Mol Cancer Ther. 2009. PMID: 19190118 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year